Competitive LandscapeUncertainty exists regarding how oral GLP-1 therapies will position alongside established injectable formulations in the obesity treatment market.
Market ChallengesPharmacy benefit manager access remains a challenge for new entrants in the oral obesity treatment space, potentially limiting market penetration.
Regulatory And Development RisksQuestions remain whether competitor molecules with a similar danuglipron-like backbone will encounter similar issues, which could impact the market dynamics.